ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
18,70
Prix Achat
18,50
Prix Vente
19,20
Volume échangé
2 367
18,70 Fourchette du Jour 18,85
16,30 Plage de 52 semaines 21,90
Cap du marché
Clôture Veille
18,70
Ouverture
18,70
Dernière Transaction
50
@
18.7
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
8 633
Actions en circulation
40 397 605
Rendement du Dividende
-
Ratio Cours sur Bénéfices
0,00
Bénéfice par action (BPA)
-
Chiffre d'affairess
25,12M
Bénéfice net
-6,16M

À propos de Philogen Spa

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
Siège social
Siena, Siena, Ita
Fondé
-
Philogen Spa est coté dans le secteur Pharmaceutical Preparations de la Italian Stock Exchange avec le ticker PHIL. Le dernier cours de clôture d'Philogen était de 18,70 €. Au cours de la dernière année, les actions de Philogen ont été négociées dans une fourchette de prix de 16,30 € à 21,90 €.

Philogen compte actuellement 40 397 605 actions en circulation. La capitalisation boursière d'Philogen est de 755,44 € million.

PHIL Dernières nouvelles

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue...

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities SIENA, Italy, Dec. 05, 2023...

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors Novel...

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial...

Philogen Announces Clinical Trial Collaboration with MSD

Philogen Announces Clinical Trial Collaboration with MSD The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy™ in combination with...

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand Mumbai...

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich Philogen Publishes New Data on a...

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology Philogen Announces Publication...

Philogen Provides Corporate Update

Philogen Provides Corporate Update Philogen Provides Corporate Update Nidlegy™ and Fibromun pivotal clinical trials on track Fibromun shows potent activity in last-line glioblastoma in...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.5-2.6041666666719.219.3518.55793818.91621737DE
4-1.25-6.265664160419.9520.518.55658819.44773709DE
12-1.6-7.8817733990120.321.318.55863319.88653388DE
26-2.5-11.792452830221.221.918.55666720.20092567DE
520.754.178272980517.9521.916.3971318.915764DE
1564.2429.322268326414.4621.913883816.74034285DE
2601.7101721.912.61222316.00431387DE

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
WSOGESWarr Soges Group
0,0629 €
(46,28%)
15,7k
DOVAADovalue AA
4,50 €
(36,36%)
1,62M
WSIAVSiav Spa
0,025 €
(29,53%)
540
PORPortobello SPA
2,42 €
(25,39%)
56,25k
WTWL26TraWell Co SA
0,26 €
(24,88%)
10
TALEAATalea Group AA
0,003 €
(-67,39%)
1,41M
WGML25GM Leather spa
0,0105 €
(-30,00%)
12k
FDAFidia
0,0704 €
(-20,90%)
3,71M
WS3D25Solid World Group spa
0,1351 €
(-14,22%)
7,01k
WEGB26EGlobe SpA
0,018 €
(-12,62%)
10k
TITTelecom Italia SpA
0,2396 €
(1,14%)
186,4M
ISPIntesa Sanpaolo Spa
3,837 €
(0,55%)
51,83M
RNRisanamento
0,0278 €
(7,75%)
30,27M
SPMSaipem Spa
2,493 €
(-1,93%)
29,12M
STLAMStellantis NV
12,918 €
(2,95%)
26,74M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock